Cellebrite: 3 Key Takeaways for Long-Term Investors
Cellebrite reported Q3 2026 results showing 20% year-over-year ARR growth to $528.5 million, driven by strong adoption of its new Genesis AI platform which generated $2 million in ARR in its first full quarter. The company plans to redomicile to the U.S. in 2027 to reduce procurement friction, though conversion uplift from its core Inseyets software is tapering off. Management expects 30% free cash flow margin for the full year as subscription revenue reaches 91% of sales.


